In contrast, high C6orf141 expression was observed to be associated with a more favorable survival curve than that of low C6orf141 expression in patients with head and neck cancer, breast cancer, ovarian cancer, and endometrial cancer. This evidence concerns the gene C6orf141 and breast carcinoma.